File Download
  Links for fulltext
     (May Require Subscription)

Article: Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong

TitleDoxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong
Authors
Issue Date2020
PublisherAmerican Society of Hematology: OAJ. The Journal's web site is located at http://www.bloodadvances.org/
Citation
Blood Advances, 2020, v. 4 n. 20, p. 5107-5117 How to Cite?
AbstractEvidence regarding the dose-related impact of doxorubicin on subsequent cardiovascular diseases (CVDs) in Asian patients with diffuse large B-cell lymphoma (DLBCL) without preexisting CVDs is lacking. From a territory-wide electronic database in Hong Kong, we identified adults who were diagnosed with DLBCL and treated with chemotherapy between 2000 and 2018. We evaluated the patients for incident CVDs (including ischemic heart disease, heart failure, and cardiomyopathy). We evaluated the cause-specific cumulative incidence (csCI) of CVD with levels of doxorubicin exposure by using flexible parametric competing risk analysis and adjusting for demographics, comorbidities, therapeutic exposure, cardiovascular risk factors, and lifestyle factors. Controls were age- and sex-matched to DLBCL patients. We analyzed 2600 patients and 13 000 controls. The adjusted cause-specific hazard ratio (HR) for CVD in patients treated with >500 mg doxorubicin compared with non-doxorubicin regimens was 2.65 (95% confidence interval [CI], 1.23-5.74; P = .013). The 5-, 10-, and 15-year csCIs were 8.2%, 11.3%, and 12.8% in patients vs 3.1%, 4.4%, and 5.2% in controls, respectively. Hypertension (HR, 6.20; 95% CI, 0.79-48.44; P = .082) and use of aspirin/angiotensin-converting enzyme inhibitor/beta-blocker at baseline (HR, 2.13-4.63; P < .001 to .002) might confer a higher risk of subsequent CVDs. In this Hong Kong population-based study, doxorubicin exposure (absolute dose >500 mg), together with hypertension or baseline use of medication for cardiovascular risk factors, was found to be associated with an increase in csCIs of CVDs. Tailoring therapeutic strategies to underlying CVD risk factors and risk-adapted monitoring and follow-up of susceptible DLBCL patients are advisable.
Persistent Identifierhttp://hdl.handle.net/10722/293336
ISSN
2023 Impact Factor: 7.4
2023 SCImago Journal Rankings: 3.065
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, SF-
dc.contributor.authorLuque-Fernandez, MA-
dc.contributor.authorChen, YH-
dc.contributor.authorCatalano, PJ-
dc.contributor.authorChiang, CL-
dc.contributor.authorWan, EYF-
dc.contributor.authorWong, ICK-
dc.contributor.authorChen, MH-
dc.contributor.authorNg, AK-
dc.date.accessioned2020-11-23T08:15:17Z-
dc.date.available2020-11-23T08:15:17Z-
dc.date.issued2020-
dc.identifier.citationBlood Advances, 2020, v. 4 n. 20, p. 5107-5117-
dc.identifier.issn2473-9529-
dc.identifier.urihttp://hdl.handle.net/10722/293336-
dc.description.abstractEvidence regarding the dose-related impact of doxorubicin on subsequent cardiovascular diseases (CVDs) in Asian patients with diffuse large B-cell lymphoma (DLBCL) without preexisting CVDs is lacking. From a territory-wide electronic database in Hong Kong, we identified adults who were diagnosed with DLBCL and treated with chemotherapy between 2000 and 2018. We evaluated the patients for incident CVDs (including ischemic heart disease, heart failure, and cardiomyopathy). We evaluated the cause-specific cumulative incidence (csCI) of CVD with levels of doxorubicin exposure by using flexible parametric competing risk analysis and adjusting for demographics, comorbidities, therapeutic exposure, cardiovascular risk factors, and lifestyle factors. Controls were age- and sex-matched to DLBCL patients. We analyzed 2600 patients and 13 000 controls. The adjusted cause-specific hazard ratio (HR) for CVD in patients treated with >500 mg doxorubicin compared with non-doxorubicin regimens was 2.65 (95% confidence interval [CI], 1.23-5.74; P = .013). The 5-, 10-, and 15-year csCIs were 8.2%, 11.3%, and 12.8% in patients vs 3.1%, 4.4%, and 5.2% in controls, respectively. Hypertension (HR, 6.20; 95% CI, 0.79-48.44; P = .082) and use of aspirin/angiotensin-converting enzyme inhibitor/beta-blocker at baseline (HR, 2.13-4.63; P < .001 to .002) might confer a higher risk of subsequent CVDs. In this Hong Kong population-based study, doxorubicin exposure (absolute dose >500 mg), together with hypertension or baseline use of medication for cardiovascular risk factors, was found to be associated with an increase in csCIs of CVDs. Tailoring therapeutic strategies to underlying CVD risk factors and risk-adapted monitoring and follow-up of susceptible DLBCL patients are advisable.-
dc.languageeng-
dc.publisherAmerican Society of Hematology: OAJ. The Journal's web site is located at http://www.bloodadvances.org/-
dc.relation.ispartofBlood Advances-
dc.rights© 2020 by The American Society of Hematology-
dc.titleDoxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong-
dc.typeArticle-
dc.identifier.emailChen, YH: eyhchen@hku.hk-
dc.identifier.emailChiang, CL: chiangcl@hku.hk-
dc.identifier.emailWan, EYF: yfwan@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authorityChen, YH=rp00392-
dc.identifier.authorityChiang, CL=rp02241-
dc.identifier.authorityWan, EYF=rp02518-
dc.identifier.authorityWong, ICK=rp01480-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1182/bloodadvances.2020002737-
dc.identifier.pmid33085755-
dc.identifier.pmcidPMC7594396-
dc.identifier.scopuseid_2-s2.0-85096223804-
dc.identifier.hkuros319938-
dc.identifier.volume4-
dc.identifier.issue20-
dc.identifier.spage5107-
dc.identifier.epage5117-
dc.identifier.isiWOS:000582796200014-
dc.publisher.placeUnited States-
dc.identifier.issnl2473-9529-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats